Molecular Characterization of Vancomycin-resistant Enterococci Repopulating the Gastrointestinal Tract Following Treatment with a Novel Glycolipodepsipeptide, Ramoplanin

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2002 Mar 30

PMID 11923325

Citations 2

Authors

L R Baden

I A Critchley

D F Sahm

W So

M Gedde

S Porter

R C Moellering Jr

G Eliopoulos

Affiliations

Soon will be listed here.

Abstract

We characterized baseline and repopulating stool isolates recovered during a phase II trial of ramoplanin for the treatment of patients with stool carriage of vancomycin-resistant enterococci (VRE). Repopulation with a strain with a related genotype was found in 74, 60, and 53% of individuals in groups treated with placebo, 100 mg of ramoplanin, and 400 mg of ramoplanin, respectively. All ramoplanin-treated patients with a culture positive for VRE at day 7 had a relapse caused by a genotypically related isolate. In ramoplanin-treated patients, antibiotics with activities against anaerobic organisms were associated with positive cultures on day 7 (relative risk [RR] = 8.8; P = 0.004), and the avoidance of such antibiotics was significantly associated with culture negativity through day 21 (RR = 0.16; P = 0.02).

Citing Articles

Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management.

ODriscoll T, Crank C Infect Drug Resist. 2015; 8:217-30.

PMID: 26244026 PMC: 4521680. DOI: 10.2147/IDR.S54125.

Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice.

Stiefel U, Pultz N, Helfand M, Donskey C Antimicrob Agents Chemother. 2004; 48(6):2144-8.

PMID: 15155213 PMC: 415563. DOI: 10.1128/AAC.48.6.2144-2148.2004.

References

Murray B . Vancomycin-resistant enterococcal infections. N Engl J Med. 2000; 342(10):710-21. DOI: 10.1056/NEJM200003093421007. View

Weinstein M, Dedier H, Brunton J, Campbell I, Conly J . Lack of efficacy of oral bacitracin plus doxycycline for the eradication of stool colonization with vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 1999; 29(2):361-6. DOI: 10.1086/520216. View

Tenorio A, Badri S, Sahgal N, Hota B, Matushek M, Hayden M . Effectiveness of gloves in the prevention of hand carriage of vancomycin-resistant enterococcus species by health care workers after patient care. Clin Infect Dis. 2001; 32(5):826-9. DOI: 10.1086/319214. View

Mondy K, Shannon W, Mundy L . Evaluation of zinc bacitracin capsules versus placebo for enteric eradication of vancomycin-resistant Enterococcus faecium. Clin Infect Dis. 2001; 33(4):473-6. DOI: 10.1086/321895. View

Wong M, Kauffman C, Standiford H, Linden P, Fort G, Fuchs H . Effective suppression of vancomycin-resistant Enterococcus species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin. Clin Infect Dis. 2001; 33(9):1476-82. DOI: 10.1086/322687. View

Baden L, Thiemke W, Skolnik A, Chambers R, Strymish J, Gold H . Prolonged colonization with vancomycin-resistant Enterococcus faecium in long-term care patients and the significance of "clearance". Clin Infect Dis. 2001; 33(10):1654-60. DOI: 10.1086/323762. View

Fu K, Lasinski E, Zoganas H, Kimble E, KONOPKA E . Therapeutic efficacy and pharmacokinetic properties of rifampicin in a Bacteroides fragilis intra-abdominal abscess. J Antimicrob Chemother. 1984; 14(6):633-40. DOI: 10.1093/jac/14.6.633. View

Fu K, Lasinski E, Zoganas H, Kimble E, KONOPKA E . Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections. J Antimicrob Chemother. 1985; 15(5):579-85. DOI: 10.1093/jac/15.5.579. View

Caufield P, Allen D, Childers N . In vitro susceptibilities of suspected periodontopathic anaerobes as determined by membrane transfer assay. Antimicrob Agents Chemother. 1987; 31(12):1989-93. PMC: 175840. DOI: 10.1128/AAC.31.12.1989. View

10.

Goering R, Winters M . Rapid method for epidemiological evaluation of gram-positive cocci by field inversion gel electrophoresis. J Clin Microbiol. 1992; 30(3):577-80. PMC: 265112. DOI: 10.1128/jcm.30.3.577-580.1992. View

11.

OHara P, Torabinejad M, Kettering J . Antibacterial effects of various endodontic irrigants on selected anaerobic bacteria. Endod Dent Traumatol. 1993; 9(3):95-100. DOI: 10.1111/j.1600-9657.1993.tb00258.x. View

12.

Mobarakai N, Quale J, Landman D . Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994; 38(2):385-7. PMC: 284464. DOI: 10.1128/AAC.38.2.385. View

13.

ODonovan C, Fan-Havard P, Smith S, Eng R . Enteric eradication of vancomycin-resistant Enterococcus faecium with oral bacitracin. Diagn Microbiol Infect Dis. 1994; 18(2):105-9. DOI: 10.1016/0732-8893(94)90074-4. View

14.

Montecalvo M, Horowitz H, Wormser G, Seiter K, Carbonaro C . Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1995; 39(3):794. PMC: 162631. DOI: 10.1128/AAC.39.3.794. View

15.

Tenover F, Arbeit R, Goering R, Mickelsen P, Murray B, Persing D . Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995; 33(9):2233-9. PMC: 228385. DOI: 10.1128/jcm.33.9.2233-2239.1995. View

16.

Landman D, Quale J, Burney S, Kreiswirth B, Willey B . Treatment of experimental endocarditis caused by multidrug resistant Enterococcus faecium with ramoplanin and penicillin. J Antimicrob Chemother. 1996; 37(2):323-9. DOI: 10.1093/jac/37.2.323. View

17.

Van Horn K, Gedris C, Rodney K . Selective isolation of vancomycin-resistant enterococci. J Clin Microbiol. 1996; 34(4):924-7. PMC: 228918. DOI: 10.1128/jcm.34.4.924-927.1996. View

18.

Rao G, Ghanekar K, Ojo F . Selective medium for screening for vancomycin-resistant enterococci in faeces. Eur J Clin Microbiol Infect Dis. 1996; 15(2):175-7. DOI: 10.1007/BF01591495. View

19.

Gold H, Moellering Jr R . Antimicrobial-drug resistance. N Engl J Med. 1996; 335(19):1445-53. DOI: 10.1056/NEJM199611073351907. View

20.

Rolston K, Dholakia N, Ho D, LeBlanc B, Dvorak T, Streeter H . In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients. J Antimicrob Chemother. 1996; 38(2):265-9. DOI: 10.1093/jac/38.2.265. View